<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 a.m.</td>
<td>Registration, Continental Breakfast and Exhibits</td>
</tr>
<tr>
<td>7:30 a.m.</td>
<td>Welcome Announcements</td>
</tr>
<tr>
<td></td>
<td>Steven R. Alberts, M.D.</td>
</tr>
<tr>
<td>7:40 a.m.</td>
<td>Pre-Test</td>
</tr>
<tr>
<td></td>
<td>Steven R. Alberts, M.D.</td>
</tr>
<tr>
<td>SESSION I:</td>
<td>Pancreas and Neuroendocrine Cancers</td>
</tr>
<tr>
<td>MODERATOR:</td>
<td>Mark J. Truty, M.D., M.S.</td>
</tr>
<tr>
<td>7:55 a.m.</td>
<td>Advanced G3 Well Differentiated NET: Sequencing Treatment Options</td>
</tr>
<tr>
<td></td>
<td>Mohamad (Bassam) B. Sonbol, M.D.</td>
</tr>
<tr>
<td>8:15 a.m.</td>
<td>Adjuvant, Neoadjuvant and Perioperative Treatment in the Care of Patients with Resectable Pancreas Cancer (PDAC): Are We Closer to Picture Perfect?</td>
</tr>
<tr>
<td></td>
<td>Zhi Ven Fong, M.D., M.P.H., Dr.P.H.</td>
</tr>
<tr>
<td>8:35 a.m.</td>
<td>NALIRIFOX, FOLFIRINOX or Gemcitabine Nab-Paclitaxel in Advanced PDAC: Who is a Candidate?</td>
</tr>
<tr>
<td></td>
<td>Michael Jon Pishvaian, M.D., Ph.D.</td>
</tr>
<tr>
<td>8:55 a.m.</td>
<td>Emerging Targets in the Treatment of Advanced PDAC: Are We Getting Closer?</td>
</tr>
<tr>
<td></td>
<td>Bassel F. El-Rayes, M.D.</td>
</tr>
<tr>
<td>9:15 a.m.</td>
<td>Panel Discussion: A Patient Undergoing Neoadjuvant Treatment in a Clearly Resectable Patient with PDAC</td>
</tr>
<tr>
<td>MODERATOR:</td>
<td>Mark J. Truty, M.D., M.S.</td>
</tr>
<tr>
<td>PANELISTS:</td>
<td>Session Presenters, Jason S. Starr, D.O.</td>
</tr>
<tr>
<td>9:45 a.m.</td>
<td>Break and Exhibits</td>
</tr>
</tbody>
</table>
SESSION II:  Biliary Tract Cancer (BTC)

MODERATOR:  Rory L. Smoot, M.D.

10:05 a.m.  Indication for Transplant in Patients with Early Stage BTC: Who is a Candidate?
Julie K. Heimbach, M.D.

10:25 a.m.  The Emerging Role of Immunotherapy in the Treatment Landscape of BTC: Is Better Selection Possible?
Lionel A. Kankeu Fonkoua, M.D.

10:45 a.m.  Advanced Endoscopic Techniques in Diagnosis and Treatment of BTC
Norio Fukami, M.D.

11:05 a.m.  Her2 as an Emerging Target in BTC
Yoshiaki Nakamura, M.D.

11:25 a.m.  Panel Discussion: A Patient with Early Stage BTC s/p Resection and Choice of Adjuvant Therapy
Moderator: Nguyen H. Tran, M.D.
Panelists: Session Presenters

11:55 a.m.  Post-Test
Steven R. Alberts, M.D.

12:15 p.m.  Adjourn

Optional Non-CME Product Theatre (Lunch provided)
Friday, March 15, 2024

6:45 a.m.  Continental Breakfast and Exhibits

7:30 a.m.  Announcements
Tanios S. Bekaii-Saab, M.D.

7:40 a.m.  Pre-Test
Tanios S. Bekaii-Saab, M.D.

SESSION III:  Hepatocellular Cancer (HCC)

MODERATOR:  Nguyen H. Tran, M.D.

7:50 a.m.  Adjuvant Therapy in Patients with High Risk HCC Treated with a Curative Intent
Anthony B. El-Khoueiry, M.D.

8:10 a.m.  Intermediate Stage HCC: At the Intersection of Systemic and Locoregional Approaches
Sadeer J. Alzubaidi, M.D.

8:30 a.m.  Optimizing Sequential Therapies in Advanced HCC
Daniel H. Ahn, D.O.

8:50 a.m.  Systemic Options Pre-Transplant: Is There an Optimal Strategy?
Thomas J. Byrne, M.D.

9:10 a.m.  Panel Discussion: A Patient with Resected Low Risk HCC and Post-op Strategy
Moderator: Sumera I. Ilyas, M.B.B.S.
Panelists: Session Presenters

9:40 a.m.  Break and Exhibits

10:00 a.m.  Special Lecture: Targeting RAS in GI Cancers
Nilofer Azad, M.D.
SESSION IV: Gastroesophageal Cancer (GE)

MODERATOR: Mohamad (Bassam) B. Sonbol, M.D.

10:20 a.m. Integrating Targeted and/or Immunotherapies in the Treatment Paradigm for Patients with Resectable GE Cancers
Harry H. Yoon, M.D.

10:45 a.m. The Expanding Landscape of Therapeutic Options for Patients with HER2+ GE Cancers
Mohamad (Bassam) B. Sonbol, M.D.

11:10 a.m. Beyond HER2 and CPI in the Treatment of Advanced GE Cancers
Jason S. Starr, D.O.

11:35 a.m. Panel Discussion: A Patient with Localized Squamous Cell Cancer
Moderator: Mohamad (Bassam) B. Sonbol, M.D.
Panelists: Session Presenters, and Daniel J. Walden, M.D.

12:05 p.m. Post-Test
Tanios S. Bekaii-Saab, M.D.

12:30 p.m. Adjourn
Optional Non-CME Product Theatre (Lunch provided)

5:00 p.m. Welcome Reception
Saturday, March 16, 2024

6:45 a.m.  Continental Breakfast and Exhibits

7:30 a.m.  Announcements
Steven R. Alberts, M.D., and Tanios S. Bekaii-Saab, M.D.

7:40 a.m.  Pre-Test
Steven R. Alberts, M.D., and Tanios S. Bekaii-Saab, M.D.

SESSION V:  Early-Stage Colorectal Cancer

MODERATOR:  Steven R. Alberts, M.D.

7:50 a.m.  Radiation Therapy in Early-Stage Rectal Cancer: Who is a Candidate?
Christopher L. Hallemeier, M.D.

8:10 a.m.  MSI-H Colon and Rectal Cancer: To Resect or Not to Resect?
Stacey A. Cohen, M.D.

8:30 a.m.  MRD Assessment in Early-Stage CRC: Who and When?
Jeremy C. Jones, M.D.

8:50 a.m.  Panel Discussion: A Patient with Localized High Rectal Cancer
Moderator: Krishan R. Jethwa, M.D.
Panelists: Session Presenters, Jewel J. Samadder, M.D.

9:30 a.m.  Break and Exhibits
SESSION VI:  Advanced Colorectal Cancer

MODERATOR: Christina S. Wu, M.D.

9:50 a.m.  HER2+ mCRC: Optimizing Diagnosis and Treatment Options
Tanios S. Bekaii-Saab, M.D.

10:10 a.m. Hyperselection for the Use of EGFR Inhibitors in First Line mCRC
Takayuki Yoshino, M.D., Ph.D.

10:30 a.m. Immunoscore and IO in Patients with MSS mCRC: Are We Getting Closer?
Rondell P. Graham, M.B.B.S.

10:50 a.m. Expanding Strategies for the Targeting of BRAF V600E MT mCRC
Mojun Zhu, M.D.

11:10 a.m. Panel Discussion: A Patient with KRAS G12C MT Colon Cancer
Moderator: Daniel H. Ahn, D.O.
Panelists: Session Presenters, and Conor O’Donnell, M.B., B.Ch., B.A.O.

11:50 a.m. Post-Test
Steven R. Alberts, M.D., and Tanios S. Bekaii-Saab, M.D.

12:10 p.m. Adjourn